Skip to Content

FDA Approves Humira

FDA Approves Humira for Rheumatoid Arthritis

Humira is a recombinant human IgGl monoclonal antibody specific for human tumor necrosis factor (TNF) indicated for reducing the signs and symptoms, inducing major clinical response, slowing the progression of joint damage, and improving physical function in adult patients with moderate to severe rheumatoid arthritis.

Posted: December 2002

Related Articles: